Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1213
- Registration Number
- NCT02807636
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇧🇪CHC MontLégia, Liege, Belgium
🇧🇦Clinical center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 81
- Registration Number
- NCT02806505
A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48950
- Registration Number
- NCT02797769
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT02795767
- Locations
- 🇺🇸
Rush Medical Center, Chicago, Illinois, United States
🇺🇸Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States
🇺🇸North Shore/Long Island Jewish PRIME; Pediatric Hematology/Oncology & Stem Cell Transplantation, New Hyde Park, New York, United States
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
- Conditions
- Bladder Cancer
- Interventions
- Biological: Bacille Calmette-Guérin
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02792192
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸VA Portland Healthcare System, Portland, Oregon, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: [18F]RO6958948
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT02792179
- Locations
- 🇺🇸
Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02791269
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02791256
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 363
- Registration Number
- NCT02788279
- Locations
- 🇺🇸
Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States
🇺🇸Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: Non-Biologic DMARDsDrug: Biological DMARDs
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4557
- Registration Number
- NCT02784808